Skip to main content

Clinical Trials on COVID-19 Corona Virus in China

COVID-19 Corona Virus Vaccine Medicine Development Clinical Trials in China

New development of COVID-19! New drug candidate discovered by Shanghai Institute of Pharmaceutical Research, Chinese Academy of Sciences

New development of COVID-19! The Chinese Academy of Sciences Shanghai Institute of Pharmaceutical Sciences has discovered new drug candidates, and another new vaccine has begun clinical trials.

At present, according to's "Tools for Fighting New Coronary Pneumonia-Epidemic Map", there are 2,551,464 people diagnosed with New Coronary Pneumonia infection worldwide and 179,695 deaths. It has become a global epidemic disease, and as of now, no curable special effects have been developed. Medicines and vaccines that can be prevented. But in order to overcome the virus and win the epidemic warfare, new news on the development of medicines and vaccines are constantly coming.

New Discovery of Anti-New Coronavirus Candidates in Shanghai Institute of Pharmaceutical Sciences, Chinese Academy of Sciences

On April 22, the official website of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences released news that the Liu Hong / Xu Yechun / Jiang Hualiang team of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, together with the Yang Haitao / Rao Zihe team of the Shanghai University of Science and Technology and the Lei Zhang / Xiao Gengfu team of the Wuhan Institute of Virology Cooperation, made important progress in the research of anti-coronavirus drugs. 
They found a class of novel, efficient, and safe anti-SARS-CoV-2 virus drug candidates. The research results were published on the bio-preprint website bioRxiv on March 28 and published online on Science on April 22.

The official website shows that the study was based on two peptoid compounds 11a and 11b designed and synthesized based on the three-dimensional structure of the coronavirus main protease. The two compounds exhibit excellent inhibitory activity against SARS-CoV-2Mpro in vitro, and have better antiviral effects. 
More importantly, both compounds exhibit good in vivo pharmacokinetic properties and safety.
Clinical Trials on Vaccines and drugs for Coronavirus COVID-19 representation

Pfizer and BioNTech's COVID-19 vaccine begins clinical trials

On April 22, Pfizer and BioNTech announced that their jointly developed BNT162 vaccine received regulatory approval from the German Federal Institute for Vaccine and Biomedical Research PaulEhrlichInstitute, and began a phase 1/2 clinical trial of the potential COVID-19 vaccine in the country.

In the first phase of clinical trials, 200 volunteers between the ages of 18 and 55 will be vaccinated with different doses of vaccines to study the optimal dose of their vaccines, as well as several different vaccines. This trial is the first clinical trial of a new coronavirus candidate vaccine started in Germany and is also part of the BNT162 global development plan.

It is reported that Pfizer and BioNTech will also conduct trials in the United States and is expected to obtain regulatory approval soon. It is worth mentioning that on March 16, Fosun Pharma and BioNTech signed a license agreement for the exclusive development and commercialization of the vaccine product for COVID-19 based on its proprietary mRNA technology platform in the region. China conducts clinical trials.

Moderna New Coronavirus Vaccine Volunteer Injects Second Injection

According to the latest news from USA Today, in the first phase of the mRNA new coronavirus vaccine mRNA-1273 trial launched by Moderna in the United States last month, Seattle volunteers who received the first injection of the vaccine are now injecting the second injection.

The mRNA-1273 vaccine was jointly developed by the National Institute of Allergy and Infectious Diseases and the American biotechnology company Moderna. It is the first new crown vaccine in the United States for clinical trials. Lisa Jackson, who led the study, said that the vaccine was taken in two doses. 
The first shot was a primer that activates the immune system, and the second shot was performed 28 days later. It established the protection formed by the first shot. Basically, if the human body is later exposed to the virus, it can produce antibodies more quickly.

Oxford University adenovirus vaccine will start clinical trials

On April 22, the British Minister of Health and the ChAdOx1 new coronavirus candidate vaccine developed by the University of Oxford is expected to begin its first human clinical trial on April 24.

ChAdOx1 was developed by researchers at the Oxford University’s Jenner Institute (Jenner Institute) and uses an adenovirus vaccine platform. It introduced the transgene encoding the new crown virus spike protein into the adenovirus vector. Adenovirus vector technology can stimulate a strong immune response through a single dose of vaccination. At the same time, the virus cannot replicate and will not cause infection in people who are vaccinated.

The World Health Organization released a new coronavirus
candidate vaccine that entered clinical trials on April 22.

Author's Bio

Name: Ian Skyler

Education: MBBS, MD

Occupation: Medical Doctor 

SpecializationCommunity Medicine, General Surgery, Natural Treatment

Experience: 18 Years as a Medical Practitioner

Share this in Public Information Interest>>


Popular posts from this blog

How to Soften and Clean Blood Vessels?

The savior that softens the blood vessels is found, eat daily, remove garbage and blood vessels clean slowly The blood vessels are densely packed in the human body, and there are many branches, which are complicated. Blood supplies oxygen and oxygen to various organs and tissues through these blood vessels to ensure the health of the body. Once there is a problem with blood vessels, it will affect blood transport and cause abnormal phenomena, which is very detrimental to health. Among them, the occurrence of blood clots in blood vessels is very serious. It can cause hardening and blockage of blood vessels, which is extremely detrimental to the health of blood vessels. For providing or getting the Best Telehealth, Telegym services and fitness networking may log in to   fitcj .com   network   What is Blood Clot? It is often referred to as blood clot. In general, there are many reasons for the formation of thrombosis, mainly due to age. Sedentary inactivity, high stress in life,

What is Vaginitis Treatment and its Prevention?

Prevention and Treatment of Vaginitis Q. I am 22 years old and just had sex this month. This time after finishing my aunt's itching, there are a lot of secretions. Did I have vaginitis? Super scared, what should I do? What should I do if my female ticket got vaginitis? OR     I have fungal vaginitis. It has not been good to reuse the medicine for 2 months. It is really shameful. I dare not let my roommate find that there is no way to go to the hospital every day.     The vagina was very itchy after coming to the aunt this time. I am now physically and mentally broken. I was nineteen and still in college. I'm not that kind of casual girl. I dare not talk to my family about such things. Too scared.    Ans. Vaginitis Study For obstetrics and gynecology, vaginitis is really the disease we are most familiar with. More than 50% of obstetrics and gynecology clinics are due to vaginitis. There are also people who originally checked for other diseases. As a result, a l

Which Molecular POCT is stronger? Point-of-Care Testing

  Molecular POCT Point-of-Care Testing Strength If you want to know which product is most popular in medical devices exhibition, it is undoubtedly molecular detection , and the most popular molecular detection is undoubtedly molecular POCT (Point-of-Care Testing). Of course, most of the domestic molecular POCT manufacturers only have relevant concepts, and some of them cannot even exhibit physical machines. Therefore, the author has sorted out some western molecular POCT manufacturers' products for your reference and hope to encourage each other. For providing or getting Best Telehealth, Telegym services and fitness networking Log in to   fitcj .com   network   1. Cepheid Device model: GeneXpert GX-IV R2, GX-XVI R2, Infinity-48s, Infinity-80   Detection throughput: 4/16/48/80   Suitable products: hospital infection, virus detection, major infectious diseases, sexually transmitted infections, tumor-related disease detection   NMPA registration status: equipment cer